Study guide
11.2 Autoimmune Hepatitis & Metabolic Liver Disease
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
11.2 Autoimmune Hepatitis & Metabolic Liver Disease
Key Takeaways Explain This Topic AI
Type 1 autoimmune hepatitis is associated with antinuclear and anti-smooth muscle antibodies; type 2 with anti-LKM1 antibodies and a younger onset.
Hereditary haemochromatosis is HFE C282Y homozygosity in most UK cases, screened with transferrin saturation above 45% and raised ferritin, and treated with venesection.
Wilson disease shows low serum caeruloplasmin, raised 24-hour urinary copper and Kayser-Fleischer rings, and is treated with penicillamine or trientine.
Last updated: September 2026
- 2. Autoimmune Hepatitis (AIH)
- Epidemiology & Immunopathogenesis
Autoimmune hepatitis is an unresolving, chronic necroinflammatory liver disease characterized by circulating autoantibodies, hypergammaglobulinaemia, and interface hepatitis on histopathology. Marked female preponderance (~4:1) with a strong immunogenetic link to HLA-DR3 (associated with aggressive, early-onset disease) and HLA-DR4 (associated with late-onset, indolent disease).
Subtypes of Autoimmune Hepatitis
Type 1 Autoimmune Hepatitis (~80% of cases):
Bimodal age distribution: peaks in adolescence/young adulthood and perimenopause (age 40–60).
Serology: Positive Antinuclear Antibodies (ANA) and/or Smooth Muscle Antibodies (SMA) , specifically directed against F-actin . Serum immunoglobulin G (IgG) is markedly elevated (polyclonal hypergammaglobulinaemia).
Clinical course: Variable, from insidious fatigue and fluctuating jaundice to acute severe hepatitis; responds favorably to systemic glucocorticoid therapy.
Type 2 Autoimmune Hepatitis (~20% of cases):
Primarily affects female children, adolescents, and young adults (age 2–14 years).
Serology: Characterized by Anti-Liver-Kidney Microsomal type 1 antibodies (anti-LKM1) , directed against cytochrome P450 2D6 (CYP2D6), or Anti-Liver Cytosol type 1 antibodies (anti-LC1) . Total IgG may be normal or only mildly elevated.
Clinical course: Often presents acutely with severe, aggressive hepatitis; higher rate of acute liver failure, frequent treatment failure, and early progression to cirrhosis.
Histopathological Hallmarks (Liver Biopsy)
Liver biopsy is mandatory for definitive diagnosis, staging, and grading:
Interface Hepatitis (Piecemeal Necrosis): Dense inflammatory infiltrate extending from portal tracts across the limiting plate into the surrounding lobular parenchyma, causing apoptotic destruction of periportal hepatocytes.
Plasma Cell Infiltration: Marked predominance of mature plasma cells and T-lymphocytes within the portal tracts.
Hepatocyte Rosetting & Emperipolesis: Hepatocytes arranged in pseudo-rosettes around collapsed reticulin fibres; active penetration of intact lymphocytes into the cytoplasm of viable hepatocytes (emperipolesis).
Pharmacological Management
Induction of Remission: High-dose oral prednisolone (30–40 mg daily, tapered over 4–8 weeks based on biochemical improvement). In non-cirrhotic patients with mild disease, oral budesonide (9 mg daily) may be used to minimize systemic steroid toxicities due to high (~90%) first-pass hepatic metabolism (strictly avoided in cirrhosis due to portosystemic shunting bypassing hepatic clearance).
Maintenance Therapy: Oral azathioprine (1–2 mg/kg/day) is added once transaminases decline to maintain remission and permit steroid withdrawal. Thiopurine methyltransferase (TPMT) activity or genotype must be established prior to initiating azathioprine to prevent lethal bone marrow aplasia. Maintenance therapy is continued for a minimum of 2–3 years; premature cessation leads to high relapse rates (>70–80%). Second-line immunosuppressants include mycophenolate mofetil (MMF) or tacrolimus .
- 3. Metabolic Liver Diseases
- Hereditary Haemochromatosis (HH)
Genetics & Molecular Pathophysiology:
Autosomal recessive disorder of iron homeostasis caused by mutations in the HFE gene on chromosome 6p21.3 (HLA-linked). The most common mutation is C282Y homozygosity (substitution of tyrosine for cysteine at amino acid position 282), accounting for ~85–90% of clinical cases. Compound heterozygotes ( C282Y / H63D ) exhibit lower penetrance.
Mechanism: Wild-type HFE protein regulates iron sensing by forming a complex with transferrin receptor 1 (TfR1) on hepatocytes, stimulating the transcription of hepcidin (the master iron-regulatory hormone). Mutant HFE fails to traffic to the plasma membrane, resulting in inappropriately low hepcidin synthesis . Low hepcidin leads to uninhibited, continuous cell-surface expression of ferroportin (the principal basolateral iron export channel on duodenal enterocytes and reticuloendothelial macrophages). Consequently, duodenal iron absorption surges uncontrollably (2–4 mg/day vs physiological 1 mg/day), saturating transferrin and resulting in toxic parenchymal accumulation of non-transferrin-bound free iron (haemosiderin) in the liver, pancreas, heart, joints, and pituitary gland.
Clinical Manifestations: Classically presents in males aged 40–60 years (delayed in females until postmenopause due to physiological iron loss via menstruation and childbirth):
Hepatic: Hepatomegaly, elevated transaminases, micronodular cirrhosis, and an extraordinarily high risk of hepatocellular carcinoma (HCC, 20- to 200-fold increase) . Exam rule: Even after complete iron depletion via venesection, patients with pre-existing cirrhosis retain a persistently elevated lifetime risk of HCC, requiring lifelong 6-monthly ultrasound surveillance.
Endocrine & Cutaneous ("Bronze Diabetes"): Slate-grey or bronze cutaneous hyperpigmentation (melanin hypersecretion combined with dermal haemosiderin deposition) and diabetes mellitus secondary to iron deposition within pancreatic beta-islet cells.
Musculoskeletal Arthropathy: Present in ~50% of patients. Classically affects the second and third metacarpophalangeal (MCP) joints and wrists, manifesting with pain, stiffness, bony enlargement, and hook-like osteophytes. Plain radiography reveals joint space narrowing, subchondral cysts, and chondrocalcinosis (calcium pyrophosphate dihydrate [CPPD] / pseudogout) . High-yield fact: Arthropathy does NOT improve with venesection therapy!
Cardiovascular: Dilated cardiomyopathy (less commonly restrictive pattern) with congestive heart failure and cardiac conduction abnormalities / refractory tachyarrhythmias (atrial fibrillation, supraventricular tachycardia). Cardiac dysfunction is reversible with timely iron removal.
Endocrine (Pituitary): Anterior pituitary iron deposition causes hypogonadotrophic hypogonadism (loss of libido, erectile dysfunction, testicular atrophy, amenorrhoea).
Diagnostic Pathway:
Initial Screening Investigation: Fasting Transferrin Saturation (serum iron / total iron-binding capacity [TIBC]). A value >50% in females or >55% in males is the most sensitive and earliest biochemical abnormality.
Serum Ferritin: Marker of total body iron storage. Ferritin >1000 ug/L strongly correlates with advanced hepatic fibrosis or cirrhosis and warrants formal fibrosis staging.
Confirmatory Genetic Testing: Targeted PCR for HFE mutations (C282Y and H63D).
Liver MRI (T2 Gradient Echo): * Accurately quantifies hepatic and myocardial iron concentration non-invasively.
Therapeutic Management:
Therapeutic Venesection (Phlebotomy): First-line treatment. Weekly or fortnightly removal of 500 mL of whole blood (~250 mg elemental iron) until the induction target is reached: serum ferritin 50–100 ug/L and transferrin saturation <50% . Thereafter, lifelong maintenance venesection is performed every 2–4 months to maintain ferritin between 50–100 ug/L.
Iron Chelation: Reserved strictly for patients with severe anaemia, severe cardiac failure, or poor venous access where venesection is contraindicated. Oral deferasirox or subcutaneous deferoxamine .
Wilson's Disease (Hepatolenticular Degeneration)
Genetics & Pathophysiology:
Autosomal recessive disorder caused by loss-of-function mutations in the ATP7B gene on chromosome 13q14.3 , encoding a copper-transporting P-type ATPase.
Mechanism: ATP7B mediates two critical intrahepatic processes: (1) transport of copper into the trans-Golgi compartment for incorporation into apocaeruloplasmin to synthesize mature caeruloplasmin, and (2) trafficking to the canalicular membrane to excrete excess copper into bile. Defective ATP7B blocks biliary copper excretion and prevents caeruloplasmin synthesis. Toxic copper accumulates inside hepatocytes; when storage capacity is saturated, free non-caeruloplasmin-bound copper spills into the systemic circulation and deposits pathologically in the brain (basal ganglia), cornea, and kidneys.
Clinical Presentation: Typically manifests between the ages of 5 and 35 years:
Hepatic Manifestations (Younger Patients, ~Age 10–15): Acute hepatitis, chronic active hepatitis, cirrhosis, or acute liver failure. Acute Wilsonian liver failure characteristically presents with Coombs-negative intravascular haemolytic anaemia (due to massive free copper release lysing red blood cells), an exceptionally low alkaline phosphatase (ALP/bilirubin ratio <2.0), and an AST/ALT ratio >2.2.
Neuropsychiatric Manifestations (Older Patients, ~Age 15–30): Copper accumulation in the lenticular nuclei (putamen and globus pallidus) produces basal ganglia dysfunction. Dysarthria is the single most common initial neurological symptom . Other features include dystonia, Parkinsonian rigidity, masked facies, resting and postural "wing-beating" tremor, chorea, ataxia, personality deterioration, mood swings, depression, and frank psychosis.
Ophthalmic Hallmarks: Kayser-Fleischer (KF) rings —golden-brown, greenish-brown copper deposits in Descemet's membrane at the corneal limbus. Identified via slit-lamp biomicroscopy; present in >95% of patients with neurological Wilson's disease (but only ~50% with purely hepatic disease). "Sunflower" cataracts may also be observed.
Renal Tubular Dysfunction: Proximal tubular copper toxicity producing Fanconi syndrome (glycosuria, aminoaciduria, phosphaturia, renal tubular acidosis).
Diagnostic Investigations:
Serum Caeruloplasmin: Reduced (<0.20 g/L; normal 0.20–0.40 g/L). Crucial exam caveat: Caeruloplasmin is an acute-phase reactant; levels may be falsely normal during active hepatic necroinflammation, pregnancy, or estrogen therapy.
24-Hour Urinary Copper Excretion: The most sensitive non-invasive screening investigation. Exceeds >1.0 umol/24 hours (>60–100 ug/24 hours) in symptomatic disease.
Elevated Serum Free (Non-Caeruloplasmin-Bound) Copper: >25 ug/dL.
Slit-Lamp Examination: Confirms Kayser-Fleischer rings.
Liver Biopsy: Gold standard for equivocal cases; shows quantitative hepatic copper concentration >250 ug/g dry weight (normal <50 ug/g).
Management Strategy:
Copper Chelation Therapy: Initial decoppering with D-Penicillamine (chelates copper and promotes urinary excretion; co-prescribe pyridoxine / vitamin B6 to prevent deficiency; watch for nephrotoxicity, bone marrow suppression, and myasthenia-like syndromes) or Trientine dihydrochloride (preferred initial agent due to superior adverse effect profile and lower risk of neurological worsening).
Maintenance Therapy: Oral zinc salts (zinc acetate or zinc sulphate) ; zinc induces enterocyte metallothionein , which avidly binds dietary copper in intestinal epithelial cells, preventing systemic absorption and causing it to be shed in faeces.
Liver Transplantation: Curative for acute liver failure (King's College prognostic score >=11) or end-stage decompensated cirrhosis; replaces the defective ATP7B enzyme.
Alpha-1 Antitrypsin Deficiency (A1ATD)
Genetics & Allelic Variants:
Autosomal codominant disorder caused by mutations in the SERPINA1 gene on chromosome 14q32.1 , encoding alpha-1 antitrypsin (A1AT), an acute-phase serine protease inhibitor (serpin).
Normal allele is PiM (Protease inhibitor M). Deficiency alleles include PiS (mildly reduced) and PiZ (severely reduced; caused by a Glu342Lys point mutation).
PiMM: Normal homozygous phenotype (100% circulating A1AT activity).
PiMZ: Heterozygous carrier (~50–60% normal levels; minimal disease risk in isolation).
PiZZ: Homozygous severe deficiency (~10–15% normal circulating levels; high risk of juvenile cirrhosis and premature emphysema).
Pathophysiology:
Hepatic Pathology (Toxic Gain-of-Function): The Z-mutant protein undergoes abnormal conformational folding, forming insoluble polymers that become trapped inside the rough endoplasmic reticulum of periportal hepatocytes . The trapped aggregates induce chronic endoplasmic reticulum stress, autophagy exhaustion, and hepatocyte apoptosis, resulting in neonatal cholestasis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Key MRCP concept: Liver disease results from toxic intracellular protein accumulation , NOT from a lack of circulating antiprotease activity!
Pulmonary Pathology (Loss-of-Function): In the lungs, profound deficiency of circulating A1AT leaves neutrophil elastase uninhibited , leading to unrestrained proteolytic destruction of alveolar elastin. Results in premature, severe panacinar (panlobular) emphysema , predominantly affecting the lower lung zones (bases) , markedly accelerated by cigarette smoking.
Histopathology: Diagnostic hallmark on percutaneous liver biopsy is the presence of intracellular, round, eosinophilic periodic acid-Schiff (PAS)-positive, diastase-resistant globules within periportal hepatocytes.
Diagnostics & Management: Quantitative serum A1AT level; confirmatory phenotyping via isoelectric focusing or SERPINA1 genotyping. Smoking cessation is absolute. Intravenous human A1AT augmentation therapy slows emphysema progression. Liver transplantation cures the hepatic disease and the systemic biochemical defect (donor graft expresses the PiMM phenotype).
Non-Alcoholic Fatty Liver Disease (NAFLD / MASLD)
Nomenclature & Spectrum: Renamed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Defined by hepatic steatosis in the presence of at least one cardiometabolic risk factor (type 2 diabetes, obesity, dyslipidaemia, hypertension) without significant alcohol consumption (<20 g/day for women, <30 g/day for men).
Metabolic Dysfunction-Associated Steatohepatitis (MASH / NASH): Characterized histopathologically by the triad of: (1) macrovesicular steatosis (>5%), (2) hepatocyte ballooning degeneration , and (3) lobular inflammation with Mallory-Denk bodies and pericellular / perisinusoidal ("chicken-wire") fibrosis.
Non-Invasive Fibrosis Stratification:
FIB-4 Index: Non-invasive score derived from: [Age x AST] / [Platelets x sqrt(ALT)].
FIB-4 <1.30: High negative predictive value (>90%) ruling out advanced fibrosis (stage F3–F4); managed in primary care with lifestyle optimization.
FIB-4 >2.67: High positive predictive value for advanced fibrosis; warrants prompt secondary care referral for transient elastography (FibroScan) or specialist hepatology evaluation.
NAFLD Fibrosis Score (NFS): Incorporates age, BMI, impaired fasting glucose/diabetes, AST/ALT ratio, platelet count, and serum albumin.
Transient Elastography (FibroScan): Measures liver stiffness (LSM in kPa; <8 kPa rules out advanced fibrosis; >12–15 kPa indicates cirrhosis) and Controlled Attenuation Parameter (CAP in dB/m) to quantify steatosis.
Management: Lifestyle modification targeting 7–10% total body weight loss (promotes histological MASH resolution and fibrosis regression); optimization of metabolic co-morbidities (GLP-1 receptor agonists e.g., semaglutide; SGLT2 inhibitors; statins are safe and indicated to reduce cardiovascular mortality); resmetirom (thyroid hormone receptor-beta agonist) indicated for non-cirrhotic MASH with moderate-to-advanced fibrosis.